Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
NCT03940976
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG:
Afatinib
Sponsor
Peking University